St. Jude Medical (NYSE:STJ) -2.3% premarket after an FDA panel votes not to recommend its CardioMEMS implantable heart device for treating heart failure. Six of 10 members said they could not determine whether the potential benefits of the wireless pressure sensor and its supporting computer monitors outweighed potential risks.